ANSM Agence nationale de sécurité du médicament et des produits de santé in the news

The ANSM is managing a shortage of duloxetine, a medication for depression, anxiety, and nerve pain, by mobilizing stocks, advising prescribers, and guiding patients.

The ANSM warns about severe side effects and misuse of Mounjaro and Wegovy, reporting 515 serious adverse events and 17 severe cases from off-label use for weight loss.

ANSM reported 2,801 adverse effects, including 515 serious cases and 13 deaths, from GLP-1 analogue use in France between February 2025 and January 2026, with a rising concern for misuse among young women.

The third pharmacovigilance report on aGLP-1 drugs identifies serious side effects from dangerous misuses, drug interactions, and unexpected adverse events, despite confirming a favorable benefit/risk ratio when used as recommended.

The ANSM reported drug availability issues in France, with FLUOROURACILE PFIZER experiencing supply tension in hospitals and its distribution now contingent.

The ANSM is managing severe shortages of furosemide tablets by limiting new prescriptions, re-evaluating existing ones, utilizing safety stock, and exploring imports due to production issues from Viatris and Zentiva.

The ANSM's latest report on GLP-1 analogue usage for diabetes and obesity found 2,801 adverse effects, including 13 deaths, but maintains a favorable benefit/risk ratio when used correctly, while also addressing significant misuse for weight loss.

ANSM's 3rd pharmacovigilance report on GLP-1 analogues details misuse for weight loss, serious complications, drug interactions, nutritional deficiencies, and reaffirms a positive benefit-risk when used as recommended.

French health authorities launch comprehensive campaigns for the 2026-2027 winter to prevent severe respiratory infections like flu, COVID-19, and bronchiolitis through vaccination, immunization, and barrier gestures.

ANSM reports supply disruptions for several hospital-only medications, including ambrisentan, linezolid, and plerixafor, with exceptional imports and varying resolution dates.

As of October 5, 2026, France faces a supply shortage of fluoxetine 20 mg capsules and dispersible tablets, necessitating priority for pediatric initiations, with normalization anticipated by mid-October.

The ANSM has reported new disruptions and updated availability for hospital medications, including temporary imports of Ambrisentan due to shortages and qualitative rationing for ATGAM with an expected resupply by end of October 2026.

The French National Agency for Medicines and Health Products (ANSM) is alerting about fluoxetine shortages due to production issues, with normalization expected by mid-October.

The French National Agency for Medicines and Health Products announced a temporary shortage of Prozac and its generics due to production issues, prioritizing prescriptions for children and anticipating a return to normal supply by mid-October.

A temporary shortage of fluoxetine-based antidepressants is affecting pharmacies, with the ANSM implementing measures to manage supply until mid-October.

The ANSM is managing supply tensions of fluoxetine 20 mg due to production issues, with normalization expected by mid-October.

The French National Agency for Medicines and Health Products (ANSM) is reporting supply tensions for Prozac and its generics due to temporary production issues, with a return to normal expected by mid-October.

216 people reported severe adverse effects to ANSM following inguinal and abdominal hernia implant procedures, with actor Arnaud Denis's case highlighting the issue before his euthanasia.

The ANSM reported disruptions in medication availability in France, including issues with flucytosine, a TARKA LP dosage, and VOLTARENOPHTA products.

The Agence nationale de sécurité du médicament et des produits de santé (ANSM) warned about symptoms of meningioma, a benign brain tumor, potentially linked to desogestrel-based contraceptives.